Figure 1.

BRCA1 (BRast CAncer 1 gene) mutant TNBC (triple negative breast cancer) cells in response to Poly (ADP-ribose) polymerase inhibitors (PARPi). MDA-MB-436 and HCC1937 cells were treated with PARPi from 0.001 to 200 µM for 7 days, then the cell viabilities and the half maximal inhibitory concentration (IC₅₀) of the indicated PARPi were determined as described in the Methods Section. (A) Inhibition curves in the cells under the indicated PARPi treatments, the points are averaged from 3 independent assays; bars represent standerd errors (SE). (B) The bars indicate mean IC₅₀ of the indicated PARPi estimated by using the semi logarithm-transformed dose-response data with a Linear Regression model. The number presented on top of the bars indicates the mean IC₅₀ for the indicated PARPi.